bioRxiv · 10.1101/2024.10.09.617418
A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Completely Protective Multivalent Mucosal Dual Vaccine Against COVID-19 and Flu
Abstract
A multivalent, rapidly deployable, mucosal vaccine platform is desperately needed to prevent the acquisition and transmission of respiratory infections during epidemics and pandemics. We present one such bacteriophage T4-based platform, and design of dual COVID-19-Flu mucosal vaccines by exploiting its unique architecture. These include: T4s natural affinity for nasal mucosa, flexible engineering to incorporate multiple antigens, and repeat and symmetric epitope presentation for enhanced B cell responses. Hundreds of SARS-CoV-2 spike trimers and nucleocapsid proteins, and influenza hemagglutinin trimers and M2e peptides, were incorporated into a single phage, creating the highest density nanoparticle presentation yet reported. Intranasal administration of adjuvant-free vaccine induced robust mucosal immunity in mice including, neutralizing antibody and secretory IgA, lung-resident CD4+/CD8+ T cells, diverse memory B cells, and complete protection against SARS-CoV-2 and influenza challenges. The noninfectious T4 phage offers an extraordinary platform to rapidly design potent mucosal vaccines against emerging bacterial and viral threats.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhu, J., Sha, J., Batra, H., Jain, S., Wu, X., Hendrix, E., Kilgore, P. B., Sun, K., Plante, K. S., Plante, J. A., Walker, J., Tao, P., Chopra, A. K., Rao, V. B.. 2024-10-09. A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Completely Protective Multivalent Mucosal Dual Vaccine Against COVID-19 and Flu. https://doi.org/10.1101/2024.10.09.617418
Cite the original work for its findings. Save a collection to share your selection of sources.